Method and composition for treatment of skeletal dysplasias
CA 2441815 C · Owner: Hepacore Limited · Inventors: Golembo, Myriam; Yayon, Avner
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention discloses pharmaceutical compositions for the treatment of skeletal dysplasias, comprising as an active ingredient at least one natriuretic peptide. Unexpectedly, it has been shown that the natriuretic factors may be effective for bone elongation in situations of abnormal bone growth especially for Achondroplasia. The effects of the natriuretic peptide may be further enhanced by prolonging its residence time or action at the target site.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 20, 2002 and granted September 23, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 20, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 20, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.